Requests that the FDA declare that the drug product, Tolmetin Capsules 600 mg is suitable for submission in an Abbreviated New Drug Application. | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-1833

Requests that the FDA declare that the drug product, Tolmetin Capsules 600 mg is suitable for submission in an Abbreviated New Drug Application.

Documents

Comments

Key Dates

Comment Period OpensFeb 19, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Completeness Assessment Correspondence	Mar 10, 2026	--

Keywords

CDER

Suitability Petition

Senores Pharmaceuticals Inc

declare that the drug product

Tolmetin Capsules 600 mg

is suitable for submission

in an Abbreviated New Drug Application

OPEN

Data from Regulations.gov